Liefaard, Marte C. http://orcid.org/0000-0002-3692-3566
Moore, Kat S. http://orcid.org/0000-0002-5746-4098
Mulder, Lennart
van den Broek, Daan
Wesseling, Jelle http://orcid.org/0000-0002-8940-2676
Sonke, Gabe S.
Wessels, Lodewyk F. A.
Rookus, Matti
Lips, Esther H. http://orcid.org/0000-0003-3488-4935
Funding for this research was provided by:
KWF Kankerbestrijding (11105, 11105, 11105, 11105, 11105)
Centre for Transportation Engineering and Planning
Center for Translational Molecular Medicine
Article History
Received: 28 January 2022
Revised: 14 January 2023
Accepted: 19 January 2023
First Online: 10 February 2023
Change Date: 24 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-023-02371-2
Competing interests
: DvdB reports payments or honoraria for lectures, presentations, manuscript writing or educational events from Roche Diagnostics. GSS reports institutional research support from Agendia, AstraZeneca, Merck, Novartis, Roche and Seagen and consultancy fees paid to the institution from Biovica and Seagen. The other authors declare no potential conflicts of interest.
: This study was conducted in accordance with the principles of the Declaration of Helsinki. Approval for this study was obtained from the institutional review board and the ethics committee at each participating hospital (NKI IRB codes: CFMPB398, CFMPB580, CFMPB617). Each participant provided written informed consent.
: Not applicable.